Arwa Elsayed Amer
Asst. Professor
Clinico‑serological associations of urinary activated leukocyte cell adhesion molecule in systemic lupus erythematosus and lupus nephritis
Clinical Rheumatology • 2024
Publication Information
Authors
Arwa S. Amer1 · Samia M. Abdel moneam1
· Nashwa I. Hashaad1
· Eman M. Yousef1
· Dalia M. Abd El‑Hassib2
Keywords
Not Available
Journal
Clinical Rheumatology
Publisher
Springer
Volume
43
Issue
Not available
Pages
1015-1021
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Background Lupus nephritis (LN) is one of the major complications associated with Systemic Lupus Erythematosus (SLE).
Activated leukocyte cell adhesion molecule (ALCAM or CD166) is a promising urine biomarker that binds to CD6, a receptor
found on lymphocytes. This binding results in T-cell activation, proliferation, and recruitment, which causes tissue infammation and may explain the pathophysiology of LN.
Aim of work Investigate the urinary ALCAM level in SLE, study its relationship to disease activity, and clarify the association with LN activity and histopathology.
Patients and methods A case–control study was performed on 60 patients with SLE and 20 matched controls. The SLE
disease activity index (SLEDAI) and the activity of renal disease (rSLEDAI) were evaluated. Renal biopsy and uALCAM
levels were also investigated.
Results Urinary ALCAM levels were higher signifcantly in active LN patients than inactive LN patients, active and inactive
non-LN SLE, and the control group (p
Activated leukocyte cell adhesion molecule (ALCAM or CD166) is a promising urine biomarker that binds to CD6, a receptor
found on lymphocytes. This binding results in T-cell activation, proliferation, and recruitment, which causes tissue infammation and may explain the pathophysiology of LN.
Aim of work Investigate the urinary ALCAM level in SLE, study its relationship to disease activity, and clarify the association with LN activity and histopathology.
Patients and methods A case–control study was performed on 60 patients with SLE and 20 matched controls. The SLE
disease activity index (SLEDAI) and the activity of renal disease (rSLEDAI) were evaluated. Renal biopsy and uALCAM
levels were also investigated.
Results Urinary ALCAM levels were higher signifcantly in active LN patients than inactive LN patients, active and inactive
non-LN SLE, and the control group (p